Auteurs
Analysis
Allemagne
Racine
Analysis
Allemagne
Exploration
Accueil
Racine
Racine

Serveur d'exploration sur les relations entre la France et l'Australie - Analysis (Allemagne)

Index « Auteurs » - entrée « Boguslawa Karaszewska »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Bogusiawa Karaszewska < Boguslawa Karaszewska < Bohdan G Rski  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 2.
Ident.Authors (with country if any)Title
000048 (2017) Dirk Schadendorf [Allemagne] ; Georgina V. Long [Australie] ; Daniil Stroiakovski [Russie] ; Boguslawa Karaszewska [Pologne] ; Axel Hauschild [Allemagne] ; Evgeny Levchenko [Russie] ; Vanna Chiarion-Sileni [Italie] ; Jacob Schachter [Israël] ; Claus Garbe [Allemagne] ; Caroline Dutriaux [France] ; Helen Gogas [Grèce] ; Mario Mandalà [Italie] ; John B A G. Haanen [Pays-Bas] ; Céleste Lebbé [France] ; Andrzej Mackiewicz [Pologne] ; Piotr Rutkowski [Pologne] ; Jean-Jacques Grob [France] ; Paul Nathan [Royaume-Uni] ; Antoni Ribas [États-Unis] ; Michael A. Davies [États-Unis] ; Ying Zhang [États-Unis] ; Mathilde Kaper [États-Unis] ; Bijoyesh Mookerjee [États-Unis] ; Jeffrey J. Legos [États-Unis] ; Keith T. Flaherty [États-Unis] ; Caroline Robert [France]Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.
000D76 (2015) Jean Jacques Grob [France] ; Mayur M. Amonkar [États-Unis] ; Boguslawa Karaszewska [Pologne] ; Jacob Schachter [Israël] ; Reinhard Dummer [Suisse] ; Andrzej Mackiewicz [Pologne] ; Daniil Stroyakovskiy [Russie] ; Kamil Drucis [Pologne] ; Florent Grange [France] ; Vanna Chiarion-Sileni [Italie] ; Piotr Rutkowski [Pologne] ; Mikhail Lichinitser [Russie] ; Evgeny Levchenko [Russie] ; Pascal Wolter [Belgique] ; Axel Hauschild [Allemagne] ; Georgina V. Long [Australie] ; Paul Nathan [Royaume-Uni] ; Antoni Ribas [États-Unis] ; Keith Flaherty [États-Unis] ; Peng Sun [États-Unis] ; Jeffrey J. Legos [États-Unis] ; Diane Opatt Mcdowell [États-Unis] ; Bijoyesh Mookerjee [États-Unis] ; Dirk Schadendorf [Allemagne] ; Caroline Robert [France]Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

List of associated KwdEn.i

Nombre de
documents		Descripteur
2Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
2Humans
2Imidazoles (administration & dosage)
2Melanoma (drug therapy)
2Oximes (administration & dosage)
2Protein Kinase Inhibitors (therapeutic use)
2Pyridones (administration & dosage)
2Pyrimidinones (administration & dosage)
2Risk Factors
1Administration, Oral
1Adult
1Aged
1Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
1Antineoplastic Combined Chemotherapy Protocols (adverse effects)
1Biomarkers, Tumor (genetics)
1DNA Mutational Analysis
1Disease Progression
1Disease-Free Survival
1Drug Administration Schedule
1Female
1Genetic Predisposition to Disease
1Imidazoles (adverse effects)
1Imidazoles (therapeutic use)
1Indoles (administration & dosage)
1Indoles (adverse effects)
1Indoles (therapeutic use)
1Intention to Treat Analysis
1L-Lactate Dehydrogenase (metabolism)
1MAP Kinase Kinase Kinases (antagonists & inhibitors)
1MAP Kinase Kinase Kinases (metabolism)
1Male
1Melanoma (genetics)
1Melanoma (metabolism)
1Melanoma (mortality)
1Melanoma (pathology)
1Melanoma (secondary)
1Middle Aged
1Mutation
1Neoplasm Metastasis (pathology)
1Oximes (adverse effects)
1Oximes (therapeutic use)
1Phenotype
1Predictive Value of Tests
1Prognosis
1Prospective Studies
1Protein Kinase Inhibitors (administration & dosage)
1Protein Kinase Inhibitors (adverse effects)
1Proto-Oncogene Proteins B-raf (antagonists & inhibitors)
1Proto-Oncogene Proteins B-raf (genetics)
1Pyridones (adverse effects)
1Pyridones (therapeutic use)
1Pyrimidinones (adverse effects)
1Pyrimidinones (therapeutic use)
1Quality of Life
1Skin Neoplasms (drug therapy)
1Skin Neoplasms (genetics)
1Skin Neoplasms (mortality)
1Skin Neoplasms (pathology)
1Sulfonamides (administration & dosage)
1Sulfonamides (adverse effects)
1Sulfonamides (therapeutic use)
1Surveys and Questionnaires
1Survival Analysis
1Time Factors
1Treatment Outcome

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Boguslawa Karaszewska" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i  \
                -Sk "Boguslawa Karaszewska" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Allemagne
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Boguslawa Karaszewska
}}
Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024